{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/obsessive-compulsive-disorder/prescribing-information/clomipramine/","result":{"pageContext":{"chapter":{"id":"32401b30-535f-57bf-8154-4e5efa0884e3","slug":"clomipramine","fullItemName":"Clomipramine","depth":2,"htmlHeader":"<!-- begin field e04b93fb-05da-47a7-b7d0-a91100c4d197 --><h2>Clomipramine</h2><!-- end field e04b93fb-05da-47a7-b7d0-a91100c4d197 -->","summary":"","htmlStringContent":"<!-- begin item 80072b8d-e36e-47cc-9710-a91100c4d0f3 --><!-- end item 80072b8d-e36e-47cc-9710-a91100c4d0f3 -->","topic":{"id":"1f37cc0e-7573-58d0-a414-18973c123eae","topicId":"394f419d-3ab3-4fd3-85c7-7ae0c286d323","topicName":"Obsessive-compulsive disorder","slug":"obsessive-compulsive-disorder","lastRevised":"Last revised in June 2018","chapters":[{"id":"6854ef67-5e05-528c-afeb-b7680f464892","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0151ee13-83cc-5d06-9ce4-f03bc14a2d91","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6ac8f0f-9ef4-5778-82e7-0ee23afbaaf8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f571042f-c058-5f39-a22d-6901a3f9f4d0","slug":"changes","fullItemName":"Changes"},{"id":"31a9215e-18d0-5bd1-9341-846c7185dd16","slug":"update","fullItemName":"Update"}]},{"id":"39a21515-e7bc-515d-80d4-420f429a801f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9c01874c-054d-55f7-bc72-c5dc572bb4ce","slug":"goals","fullItemName":"Goals"},{"id":"bb1af94d-3d5a-5862-9e75-51cfd39e9e31","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"31dd33b1-cd86-57bc-84c1-206363cae677","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8aa2028a-8646-59f5-ac0b-c585d5f9474a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"96f32bee-6f1f-5862-8163-8f9adf02e81e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0c41f244-6591-5043-825b-f48000a19060","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"69296d43-e92e-51ad-803f-9b00dd4ef3eb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23304d59-7975-500a-9672-1d71c224d42b","slug":"definition","fullItemName":"Definition"},{"id":"75facf2a-3aa9-52ec-a213-c09d7c49305a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ef703cf4-f71d-53e8-ac6e-55fd3949af89","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16615ebe-7c11-54ea-8c8f-11b27bd84df0","slug":"prognosis","fullItemName":"Prognosis"},{"id":"9c3a46c7-846c-5e14-9297-e80dfc82ffa5","slug":"complications","fullItemName":"Complications"}]},{"id":"9063127c-d315-5f06-81a4-0854a79730a5","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8e2a1f2f-09ef-5f73-a3ec-2aac2b0a90b7","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"d07d5382-3d58-534c-80b0-ebb514c9d790","fullItemName":"Management","slug":"management","subChapters":[{"id":"adfa1e25-924b-5e4d-b909-bbd62bfa3981","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"1a83f73e-9ca7-5f30-9cda-aaa563048a36","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0b63ad08-27a9-5af8-8fb8-6940aa3d3dc3","slug":"ssris","fullItemName":"SSRIs"},{"id":"32401b30-535f-57bf-8154-4e5efa0884e3","slug":"clomipramine","fullItemName":"Clomipramine"}]},{"id":"34094942-974d-50ae-b83e-52a2243c1e47","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"06ebd4e9-a6ff-5645-8bf1-4a06d03e073b","slug":"psychological-treatments-in-adults","fullItemName":"Psychological treatments in adults"},{"id":"73a36a4c-8f66-5d63-a4ad-c1667bd42f3b","slug":"ssris-in-adults","fullItemName":"SSRIs in adults"},{"id":"f077f54e-c77f-533b-84b3-6f81c9eb4f89","slug":"pharmacological-versus-psychological-treatments-in-adults","fullItemName":"Pharmacological versus psychological treatments in adults"},{"id":"d63bb159-7b2d-54b3-a251-0fb81b09618f","slug":"combination-treatments-in-adults","fullItemName":"Combination treatments in adults"}]},{"id":"ed477751-4d36-5e3b-bfcb-60739e1daea7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6e26607d-6208-5c71-a5ee-ba2bd8567311","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"700ff2f4-6d6b-5235-8301-91ad6701f206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"20682403-8c70-5f97-86c4-1f8234b42261","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9242ca74-0efb-54f8-9cb4-267acc46dc6c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8a264e61-1997-5859-8b1d-e1d859ffa219","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c91ccb0b-b8e6-5c2a-ab14-79b9eff3e63a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1a83f73e-9ca7-5f30-9cda-aaa563048a36","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8d5d0934-83c7-5793-878a-507e2936dd9a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field bf914a29-44bd-4381-aa16-a91100c56fed --><h3>Contraindications and cautions</h3><!-- end field bf914a29-44bd-4381-aa16-a91100c56fed -->","summary":"","htmlStringContent":"<!-- begin item d8810598-3b03-4fa0-9352-a91100c56dea --><!-- begin field ff8cf97a-6921-438c-9f16-a91100c56fed --><ul><li><strong>Do not prescribe clomipramine to people with:</strong><ul><li>Acute porphyrias.</li><li>Recent myocardial infarction, any degree of heart block, or other cardiac arrhythmias.</li><li>Severe liver disease.</li><li>Concurrent administration with monoamine oxidase inhibitors or within 3 weeks of start or cessation of therapy.</li><li>Concomitant treatment with selective, reversible MAO-A inhibitors, such as moclobemide.</li><li>Narrow-angle glaucoma.</li><li>Retention of urine.</li><li>Mania.</li><li>Hypokalaemia — hypokalaemia should be treated before initiating treatment with clomipramine.</li></ul></li><li><strong>Prescribe clomipramine with caution to people with:</strong><ul><li>Hepatic or renal impairment — in people with hepatic and renal disease, periodic monitoring of hepatic enzyme levels and renal function is recommended.</li><li>Cardiovascular disorders, especially cardiovascular insufficiency, conduction disorders, (e.g. atrioventricular block grades I to III), arrhythmias — check blood pressure and conduct an electrocardiogram (ECG) before prescribing clomipramine for adults at significant risk of cardiovascular disease.</li><li>Epilepsy or other predisposing factors for seizure such as brain damage of varying aetiology, concomitant use of neuroleptics, withdrawal from alcohol or drugs with anticonvulsive properties (e.g.<em> </em>benzodiazepines) — clomipramine reduces the seizure threshold and extreme caution should, therefore, be exercised.</li><li>A history of increased intraocular pressure, narrow-angle glaucoma, urinary retention or with symptoms of bladder neck obstruction, e.g. diseases of the prostate, such as prostatic hypertrophy— the anticholinergic properties of clomipramine can exacerbate these conditions.</li><li>Tumours of the adrenal medulla (e.g.<em> </em>phaeochromocytoma, neuroblastoma) — administration of clomipramine may provoke hypertensive crises.</li><li>Hyperthyroidism or concomitant treatment with thyroid preparations — aggravation of unwanted cardiac effects may occur.</li><li>Chronic constipation — tricyclic antidepressants may cause paralytic ileus, particularly in people who are older and/or bed-ridden.</li></ul></li><li><strong>Note: </strong>monitoring of cardiac function and ECG is indicated in elderly people.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">BNF 75, 2018</a>]</p><!-- end field ff8cf97a-6921-438c-9f16-a91100c56fed --><!-- end item d8810598-3b03-4fa0-9352-a91100c56dea -->","subChapters":[]},{"id":"45cedd63-8db6-568b-8fbe-3910429c1306","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ae539be4-38c8-49d2-94dd-a91100c58369 --><h3>Adverse effects</h3><!-- end field ae539be4-38c8-49d2-94dd-a91100c58369 -->","summary":"","htmlStringContent":"<!-- begin item a7e6fd89-930d-40bf-aec6-a91100c582c5 --><!-- begin field ce9f3912-3872-4334-93fe-a91100c58369 --><p><strong>The most common adverse effects of clomipramine include:</strong></p><ul><li>Increased or decreased appetite.</li><li>Psychiatric effects — restlessness, confusion, disorientation, hallucinations (particularly in older patients and those with Parkinson's disease), anxiety, agitation, sleep disorder, mania, hypomania, aggression, depersonalisation, aggravation of depression, insomnia, nightmares, delirium.</li><li>CNS effects — dizziness, tremor, headache, myoclonus, fatigue, somnolence, speech disorder, paraesthesia, hypertonia, dysgeusia, memory impairment, disturbance in attention, tinnitus.<ul><li>Advise the person that it is illegal in England and Wales to drive while taking a prescribed drug if it impairs driving [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">DVLA, 2015b</a>].</li></ul></li><li>Eye disorders — accommodation disorder, blurred vision, mydriasis.</li><li>Cardiac disorders — sinus tachycardia, palpitation, orthostatic hypotension, clinically irrelevant ECG changes (e.g.<em> </em>ST and T changes) in people of normal cardiac status.</li><li>Gastrointestinal disorders — nausea, dry mouth, constipation, vomiting, diarrhoea.</li><li>Other — hot flush, yawning, hyperhidrosis, allergic dermatitis (skin rash, urticaria), photosensitivity reaction, pruritus, muscular weakness, micturition disorder, urinary retention, libido disorder, erectile dysfunction, galactorrhoea, breast enlargement.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">BNF 75, 2018</a>]</p><!-- end field ce9f3912-3872-4334-93fe-a91100c58369 --><!-- end item a7e6fd89-930d-40bf-aec6-a91100c582c5 -->","subChapters":[]},{"id":"fde6f788-3241-53a0-bae2-d874a83a65e9","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field de632b30-4f28-4b9b-9221-a91100c59bce --><h3>Drug interactions</h3><!-- end field de632b30-4f28-4b9b-9221-a91100c59bce -->","summary":"","htmlStringContent":"<!-- begin item 3da93c10-b42f-4aee-9f4b-a91100c59a64 --><!-- begin field 2a31f8c1-706d-422a-ad2f-a91100c59bce --><p><strong>Key drug interactions with clomipramine include:</strong></p><ul><li>MAOIs — do not give clomipramine for at least 3 weeks after discontinuation of treatment with MAO inhibitors as there is a risk of severe symptoms consistent with Serotonin Syndrome such as hypertensive crisis, hyperpyrexia, myoclonus, agitation, seizures, delirium and coma). The same applies when giving a MAO inhibitor after previous treatment with clomipramine. In both instances, the treatment should initially be given in small gradually increasing doses and its effects monitored. </li><li>5HT<sub>3 </sub>— receptor antagonists, dapoxetine, duloxetine, fentanyl, Rasagiline, St John's wort, tramadol, triptans, SSRIs, SNRIs, tricyclic antidepressants and lithium — increased risk of serotonergic effects. Concurrent use not recommended.<ul><li>Fluoxetine, paroxetine, sertraline, and fluvoxamine — may increase plasma concentrations of clomipramine with corresponding adverse effects.</li><li>For fluoxetine, a wash-out period of two to three weeks is advised before commencing clomipramine treatment, with clomipramine wash-out also required if fluoxetine is subsequently to be administered.</li></ul></li><li>Diuretics — concurrent use may lead to hypokalaemia, which increases the risk of QTc prolongation and torsades de pointes. Concurrent use not recommended.</li><li>Quinidine — should not be given concurrently with clomipramine.</li><li>Pimozide — increased risk of ventricular arrhythmias. Avoid concomitant use.</li><li>Terbinafine, cimetidine, methylphenidate, sodium valproate  — co-administration may lead to increased plasma levels of clomipramine.</li><li>Phenothiazines — may result in increased plasma levels of clomipramine, a lowered convulsion threshold, and seizures. Concurrent use with thioridazine may produce severe cardiac arrhythmias.</li><li>Rifampicin,<em> </em>anticonvulsants (such as barbiturates, carbamazepine, phenobarbital and phenytoin), cholestyramine or colestipol, St. John's wort — concurrent use may decrease plasma levels of clomipramine.</li><li>Anticholinergic agents (such as phenothiazines, antiparkinsonian agents, antihistamines, atropine, biperiden),  CNS depressants (such as barbiturates, benzodiazepines, or general anaesthetics), sympathomimetic drugs, (such as adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine, and phenylpropanolamine contained in local and general anaesthetic preparations and nasal decongestants) — co-administration may potentiate the effects of these drugs. Caution is therefore advised.</li><li>Coumarins — clomipramine possibly enhances the anticoagulant effect of coumarins.<ul><li>Consider frequent monitoring of the INR. Any change in the person's clinical condition, particularly liver disease, intercurrent illness, or drug administration, necessitates more frequent monitoring of the INR. </li></ul></li><li>Guanethidine, betanidine, reserpine, clonidine and alpha-methyldopa — clomipramine may diminish or abolish the antihypertensive effects of these drugs. People requiring co-medication for hypertension should, therefore, be given antihypertensives of a different type (e.g. vasodilators, or beta-blockers).</li><li>Drugs that prolong the QT interval (such as such as certain antiarrhythmics [including quinidine, disopyramide, procainamide, amiodarone and sotalol], tricyclic antidepressants [such as amitriptyline], certain tetracyclic antidepressants [such as maprotiline], certain antipsychotic medications [such as phenothiazines and pimozide], certain antihistamines [such as terfenadine]; lithium, quinine,  and pentamidine) — co-administration increases the risk of QTc prolongation and torsades de pointes.<ul><li>Drugs that increase the plasma levels of clomipramine (including antiarrhythmics, certain antidepressants including SSRIs, tricyclic antidepressants and moclobemide; certain antipsychotics; β-blockers; protease inhibitors, opiates, cimetidine, and terbinafine) may also increase the risk of QTc prolongation and torsades de pointes if co-administered.</li></ul></li><li>Non-steroidal anti-inflammatory drugs — co-administration may lead to increased risk of bleeding.</li><li>Analgesics — possible increased side effects with nefopam; possible increased risk of convulsions with tramadol; possible increased sedation with opioid analgesics; increased risk of ventricular arrhythmias with levacetylmethadol.</li><li>Dopaminergics — concomitant use with entacapone should be avoided; central nervous system toxicity has been reported with selegiline.</li><li>Muscle relaxants — concomitant use may enhance the muscle relaxant effect of baclofen.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">BNF 75, 2018</a>]</p><!-- end field 2a31f8c1-706d-422a-ad2f-a91100c59bce --><!-- end item 3da93c10-b42f-4aee-9f4b-a91100c59a64 -->","subChapters":[]},{"id":"ced423f2-fc28-5eb6-a492-bddac10eadb5","slug":"dosing-information","fullItemName":"Dosing information","depth":3,"htmlHeader":"<!-- begin field bdb19898-37c9-4cef-a058-a91100c5b2ce --><h3>Dosing information</h3><!-- end field bdb19898-37c9-4cef-a058-a91100c5b2ce -->","summary":"","htmlStringContent":"<!-- begin item fd75c18d-6c25-459b-b82d-a91100c5b1b5 --><!-- begin field 0f76bb52-a9d3-4bc3-8a14-a91100c5b2ce --><ul><li>Initially, prescribe 25 mg each day (or 10 mg daily in the elderly).</li><li>If there are no significant adverse effects:<ul><li>Increase gradually over 2 weeks to 100–150 mg daily (increase more slowly in the elderly).</li><li>At 4–6 weeks, if there is an inadequate treatment response, increase gradually up to a maximum dose of 250 mg daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">BNF 75, 2018</a>]</p><!-- end field 0f76bb52-a9d3-4bc3-8a14-a91100c5b2ce --><!-- end item fd75c18d-6c25-459b-b82d-a91100c5b1b5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}